Posts Tagged ‘cyst’


In BUSINESS OF STEM CELLS on November 15, 2011 at 1:27 am


Embryonic stem cell treatment are now an unrealized potential.

Adult stem cell treatments are a realized potential.

To see if your condition can be treated with Adult stem cells, please fill out this form: http://bit.ly/PATIENTQUESTIONNAIRE



In STEM CELLS IN THE NEWS on November 14, 2011 at 11:13 pm





GERON THROWS IN THE TOWEL!If stem cell treatments were a boxing match, Embryonic stem cell treatments would be the 500 lb Gorilla and Adult stem cell treatments would be the small, unknown underdog.   Today, that Gorilla threw in the towel!

Despite the huge disparity in their media coverage, with positive Embryonic stem cell potential articles outnumbering all Adult stem cell articles by 1,000 to one, only Adult stem cells have a proven history of safety and efficacy, only Adult stem cell treatments are available today.  Click here to see if your condition can be treated with Adult stem cells:

While Geron and the US media, big Pharma, the AMA and the FDA have all given Embryonic stem cell their full throated support, the number of patients helped with adult stem cells is in the 10s of thousands while the number of patients helped by Embryonic stem cells in zero.

HORSE FALLING DOWN DURING RACEIf Embryonic treatments were a horse race, Geron would be the strongest horse in the field.  Geron would be the horse who was 9/10 of the way around the track with all other competitors still milling about in the starting blocks.  So what would make that horse stop dead in his tracks, fall flat on his face and walk away from the race?

What does it mean for the other Embryonic focused companies when the front runner pulls out of the race?

What would cause the leading Embryonic stem cell Pharmaceutical company with multiple Embryonic stem cell products in development to end all of their Embryonic stem cell programs? 

Product Product Description Application Development Stage
GRNOPC1 Oligodendrocyte Progenitor Cells Spinal Cord Injury Phase I Clinical Trial
GRNCM1 Cardiomyocytes Heart Disease Preclinical
GRNIC1 Islets Type 1 Diabetes Research
GRNCHND1 Chondrocytes Osteoarthritis Research
Hepatocytes ADME Drug Screening Research
GRNVAC2 Mature Dendritic Cells Cancer Immunotherapy Product Research
Immature Dendritic Cells Immune Rejection Research
Osteoblasts Osteoporosis Research

via Geron.com

Perhaps their clinical trial patients developed cysts and tumors as do all Embryonic stem cell patients.  Perhaps Geron decided to end their trials before these tumors and cysts turned into cancer so they could still say their product “has been well tolerated with no serious adverse events.”

Perhaps Geron couldn’t figure out how to address the need for immunosuppressive drugs required to implant a human with ALL Embryonic stem cells when there are many Adult stem cells that have no rejection issues.

Perhaps Geron couldn’t determine how to deal with Embryonic stem cells carrying the genetic abnormalities and maladies of the donor.

Or perhaps they read some of the quotes from my articles going back to March of 2009:

  • To date, ESC research has been 100% fruitless (in regard to generating treatments) for well-funded + government supported scientists around the world for the last 11 years.
  • Dr James Thomson, father of ESC research said: “…[ESC] are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.”
  • Ian Wilmut, who led the team that cloned Dolly the sheep, abandoned his license to attempt human cloning, saying that the researchers “may have achieved what no politician could: an end to the [ESC] debate.”
  • Dr. Bernadine Healy, former director of the NIH in U.S. News & World Report: “…[ESC], once thought to hold the cure for Alzheimer’s, Parkinson’s, and diabetes, are obsolete….. In fact, adult stem cells, which occur in small quantities in organs throughout the body for natural growth and repair, have become stars despite great skepticism early on.
Or maybe they reviewed the timeline for Embryonic stem cell success and realized they couldn’t afford 50 YEARS OF RESEARCH!
Dr. Colin McGuckin, a noted UK embryonic research leader at Newcastle U. before departing for more useful RSC research in France announced:

  • “For me, the unnecessary row over stem cells has obscured the very real issue that patients are waiting to be treated…The best estimates of the embryonic scientists in our own university in Newcastle is that embryonic stem cells may not be able to help people this side of 50 years. That’s my lifetime. And that’s worrying. We can’t wait that long.”
I do have to applaud their spin department.  It is a brilliant move to take the news story
and spin it into
Even so, we are not fooled.  The red headed step child in the family always knows when they are neglected. 
They also published their press release at 4:05 Eastern so the regular stock market was closed and couldn’t react to the news. Unfortunately for them, their stock dropped over 20% in after hours trading.
Whatever the reason for Geron abandoning Embryonic stem cells, we can now finally exalt that THE WAR IS OVER and get on with Adult Stem Cell Treatments, the only stem cells to cure a human patient.


  • SOURCE/DERIVED FROM•comes from blood, umbilical cords, bone marrow, placenta fat tissue, muscle, nasal neurological, breast milk, menstruation, dental pulp, and many more
  • PURPOSE IN BODY•they are the body’s natural healing cells
  • OBSTACLES+SIDE EFFECTS•~zero problems (virtually zero side effects)
  • TREATMENT HISTORY•used in bone marrow transplants to treat cancer for 40 years
  • TREATMENT HISTORY•can currently treat 130+ diseases safely and effectively (CP, MS, Autism, Diabetes, CHF, PAD, etc)
  • To see if your condition can be treated with Adult stem cells, please fill out this form: http://bit.ly/PATIENTQUESTIONNAIRE

via STEM CELLS 101

  • 100+ DISEASES treated around the world with adult stem cells!
  • 60-70% SUCCESS RATE typical therapeutic benefit on INCURABLE DISEASES!!
  • POTENTIAL CURES of Autism, Parkinson’s, AIDs, Diabetes, Heart Disease and more!
  • HUGE REWARDS of life extension!
  • SIGNIFICANTLY IMPROVED quality of life!


Geron to Focus on Its Novel Cancer Programs
Company Plans to Partner All Stem Cell Programs

MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN) today announced that, effective immediately, the Company will focus on its first-in-class oncology programs. As a consequence, the Company will discontinue further development of its stem cell programs and is seeking partners for these novel assets.

“Our employees, collaborators and shareholders can be proud of the pioneering role they have played to advance our stem cell technology into the clinic”

“In the current environment of capital scarcity and uncertain economic conditions, we intend to focus our resources on advancing our Phase 2 clinical trials of imetelstat and GRN1005. These two novel and promising oncology drug candidates target major unmet medical needs and have important clinical development milestones occurring over the next 20 months,” said Geron’s Chief Executive Officer, John A. Scarlett, M.D. “By narrowing our focus to the oncology therapeutic area, we anticipate having sufficient financial resources to reach these important near-term value inflection points for shareholders without the necessity of raising additional capital. This would not be possible if we continue to fund the stem cell programs at the current levels.

…The decision to narrow Geron’s technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities associated with the Company’s research and clinical-stage assets. With this decision, Geron is eliminating 66 full-time positions, representing 38% of its workforce. As a result, the Company expects one-time cash expenditures of approximately $5 million in the fourth quarter of 2011 and approximately $3 million in the first half of 2012. Geron expects to end 2011 with cash and investments in excess of $150 million.

Geron is seeking partners with the technical and financial resources to enable further development of its stem cell programs. “Our employees, collaborators and shareholders can be proud of the pioneering role they have played to advance our stem cell technology into the clinic,” said Dr. Scarlett. “Stem cells continue to hold great medical promise. We believe that our leadership role in the field and the quality of our stem cell assets — which are widely recognized as being among the most innovative, comprehensive and advanced cell therapy programs in the world — will be an important point of differentiation in our discussions to partner these assets.” In order to facilitate transfer of these programs to partners, Geron will retain a core group of employees from its stem cell operations through the end of the second quarter of 2012.

Geron plans to close the GRNOPC1 trial for spinal cord injury to further enrollment, although it will continue to follow all enrolled patients, accruing data and updating FDA and the medical community on their progress. In this trial, GRNOPC1 has been well tolerated with no serious adverse events

Read more

Related articles:



To see if your condition can be treated with Adult stem cells, please fill out this form:


In ALL ARTICLES on September 21, 2011 at 9:51 pm

Here’s an 867 word article I’d like to not waste your time with.


The premise is:  “The study is not meant to determine whether the stem cells can cure or even improve the patients’ condition, but to find out if the treatment itself is safe. Researchers will be monitoring patients over the following months and years to look for side effects, including possible benign tumor growth if the stem cells start to replicate, or adverse immune reactions.”

So let’s not waste your time, I’ll give you the results right now:


  • SOURCE/DERIVED FROM•comes from embryos
  • PURPOSE IN BODY•split for 7 weeks until you have a fetus the size of a thumbnail
  • OBSTACLES+SIDE EFFECTS•they create cysts and tumors, rejection requires immunosuppressive drugs for the ill patient, they carry the genetic anomalies of the donor, etc
  • TREATMENT HISTORY•can currently treat zero diseases, probably need to cure cancer first to use them

Read it if you want but that’s really “all she wrote.”  Then again, this will allow billions to be pumped into embryonic research for treatments over “the following months and years” despite this fact…




Paralyzed patient in major Geron stem cell study

Erin Allday, Chronicle Staff Writer, Wednesday, September 21, 2011

A Bay Area patient who recently suffered a serious spinal cord injury and is now paralyzed from the waist down joined the world’s first-ever embryonic stem cell study in humans last week, when Stanford doctors injected 2 million cells designed to replace damaged neurons in the patient’s spine.

The patient, who is not being identified, is the fourth person to be enrolled in the clinical trial being run by Menlo Park’s Geron Corp. and the first person in California. The patient, whose participation in the trial was revealed Tuesday, received the stem cell injection Saturday at Santa Clara Valley Medical Center and is now at the rehabilitation center there.

The study is not meant to determine whether the stem cells can cure or even improve the patients’ condition, but to find out if the treatment itself is safe. Researchers will be monitoring patients over the following months and years to look for side effects, including possible benign tumor growth if the stem cells start to replicate, or adverse immune reactions…

Read more


In ALL ARTICLES on September 21, 2011 at 2:19 pm

Wow, this one was devious!! Some of these articles must be read very carefully as they are misleading and confusing, perhaps even intentionally so.

http://elrodsgodisney.files.wordpress.com/2011/07/confused_mickey_mouse_poster-p228990749419197094vhwx0_328-e1309635341795.jpg?w=197&h=281They start by telling you ‘adult stem cells‘ may fight cancer….

but later in the article refer to them as ‘adult cells…’

and even later as ‘induced pluripotent stem cells.’

But don’t be fooled by this semantic sleight of hand.

Induced pluripotent stem cells are semantically ‘adult cells’ only in the sense that all cells in an adult can be referred to as adult cells.  Perhaps this is the author’s attempt to make them distinct from embryonic cells. In any case, if your friend asks you for an APPLE from the MARKET, it is not acceptable to bring him back a BAG OF FLOUR just because they both can be “found at a MARKET.”

ANd let’s be clear.  Only ADULT STEM CELLS have thousands of studies and trials and thousands of patients treated safely and effectively.  Induced pluripotent stem cells have NONE.  And while Induced pluripotent stem cells ARE a manipulated type of ‘stem cell,’ they have a lot of problems too, as the article owns up to (one of the problems) in the end:

potential side effects need to be considered. iPS cells may develop into other harmful cells in the body.”

              “other harmful cells in the body”  =  tumors, cysts, cancer



(dichotomy? I think so, makes me think of vaccines where you get injected with the disease to build anti-bodies to the disease.)

But the good news is, there are cancer treatments out there with high results and low or virtually no side effects that make chemo and radiation look ineffective and barbaric by comparison!


Stem cells, potential source of cancer-fighting T cells

ScienceDaily (Sep. 20, 2011) — Adult stem cells from mice converted to antigen-specific T cells — the immune cells that fight cancer tumor cells — show promise in cancer immunotherapy and may lead to a simpler, more efficient way to use the body’s immune system to fight cancer, according to Penn State College of Medicine researchers.

“Cancer immunotherapy is a promising method to treat cancer patients,” said Jianxsun Song, Ph.D., assistant professor, microbiology and immunology. “Tumors grow because patients lack the kind of antigen-specific T cells needed to kill the cancer. An approach called adoptive T cell immunotherapy generates the T cells outside the body, which are then used inside the body to target cancer cells.”

It is complex and expensive to expand T cell lines in the lab, so researchers have been searching for ways to simplify the process. Song and his team found a way to use induced pluripotent stem (iPS) cells, which are adult cells that are genetically changed to be stem cells.

“Any cell can become a stem cell,” Song explained. “It’s a very good approach to generating the antigen-specific T cells and creates an unlimited source of cells for adoptive immunotherapy.”

By inserting DNA, researchers change the mouse iPS cells into immune cells and inject them into mice with tumors. After 50 days, 100 percent of the mice in the study were still alive, compared to 55 percent of control mice, which received tumor-reactive immune cells isolated from donors.

Researchers reported their results and were featured as the cover story in a recent issue of the journal Cancer Research.

A limitation of this potential therapy is that it currently takes at least six weeks for the iPS cells to develop into T cells in the body. In addition, potential side effects need to be considered. iPS cells may develop into other harmful cells in the body.

Researchers are now studying how to use the process in human cells.

Other researchers on this paper are Fengyang Lei, and Rizwanul Haque, Department of Microbiology and Immunology; Lynn Budgeon and Neil D. Christensen, Ph.D., Department of Pathology, Penn State College of Medicine.

This study was funded through the Pennsylvania Department of Health using Tobacco Settlement Funds, the W.W. Smith Charitable Trust and the Melanoma Research Foundation.

FDA OKs First Embryonic Stem Cell Research Trial on Humans, Despite Concerns

In STEM CELLS IN THE NEWS on July 31, 2010 at 3:09 pm

Admiral Horatio Nelson was blinded in one eye early in his Royal Navy career. In 1801, during the Battle of Copenhagen cautious Admiral Sir Hyde Parker, in overall command of the British forces, sent a signal to Nelsons forces giving him discretion to withdraw. Naval orders were transmitted via a system of signal flags at that time. When this order was given to the more aggressive Nelson’s attention, he lifted his telescope up to his blind eye, said “I really do not see the signal”, and his forces continued to press home the attack.

The idiom,

“turning a blind eye,”

is used to describe the process of ignoring unpopular orders or inconvenient facts or activities.




1.  Most of the standard preclinical trial process

  • Preclinical testing – When a drug is discovered that seems to have medical potential, a drug company will test it exhaustively in animals, looking for signs it may be poisonous, cause cancer, or cause birth defects. Animal studies will also be used to estimate the initial drug doses to be tested in humans.When animal experiments are finished, the company asks the FDA for permission to begin clinical trials. The FDA only grants approval once they are satisfied that the animal experiments are sound and that clinical trials are likely to be safe. from

2.  Adult stem cells have successfully treated spinal cord injuryfor years (successfully!

3.  Embryonic stem cell treatments often cause cysts and tumors.  All embryonic scientists and even Geron have openly admitted this.

4.  Embryonic stem cell treatment rejection problems and the immunosuppressive drugs required tooffset them

  • Oh, well…What do spinal cord injury patients need with a healthy immune system when they are trying to get better anyway?

P.S. And by the way, please note that every single one of these issues is scientific; not moral, ethical or religious.

FDA OKs First Embryonic Stem Cell Research Trial on Humans, Despite Concerns

by Steven Ertelt
LifeNews.com Editor
July 30
, 2010

// Washington, DC (LifeNews.com) — The Obama administration has approved the bid by cloning company Geron to undertake the first trial involving the use of embryonic stem cells in humans. They have never been used before in people because the cells cause tumors and have been plagued by immune system rejection issues when tried in animals.

Scientists and pro-life advocates say human embryonic stem cells are not ready for trial because problems associated with the cells in animals haven’t been solved.

The Food and Drug Administration had initially placed the trial on hold but Geron indicated today that the agency is now allowing it to proceed with an early stage trial on a stem cell therapy for acute spinal cord injury.

The FDA placed a hold on the trial last August, when evidence showed Geron’s GRNOPC1 encountered safety issues when used in animal studies. Geron’s own data showed higher frequency of small cysts within the injury site in the spinal cord of animals injected with the embryonic cells.

“We are pleased with the FDA’s decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed,” said Thomas B. Okarma, Geron’s president, in a public statement today. The company’s stock rose in value following the announcement.

Previously, Dr. John A. Kessler, chairman of neurology and director of the stem cell institute at Northwestern University, said the first application from Geron for the embryonic stem cell trial was flawed.

“We really want the best trial to be done for this first trial, and this might not be it,’’ he said at the time.

Responding to the news today, Dr. David Prentice, a former biology professor at Indiana State University who is now a fellow at the Family Research Council, tells LifeNews.com those concerns should still exist.

“It’s unfortunate that the FDA has released Geron from the safety hold on their embryonic stem cell trial,” he said. “Even many pro-embryonic stem cell scientists have expressed reservations about Geron’s trial, that it is not proven even in rats. The concern for many of us is that Geron is endangering patient’s health and very lives, to make a political point and increase their stock price.”

Prentice also said the trial’s approval makes it so the use of adult stem cells, which are safely helping patients battling more than 100 diseases and conditions already, continue to be ignored.

“In the meantime, adult stem cells have already shown published scientific evidence for safety and successful repair of spinal cord injury in patients. Only adult stem cells offer both an ethical and successful path to healing,” he said.

Prentice also explained that the trial isn’t precisely the first one involving embryonic stem cells — making it so media outlets need to fully explain what Geron is doing.

“They inject cells derived from embryonic stem cells; in this case a cell type called an oligodendrocyte, which is a cell that forms a sheath, like insulation, around nerve fibers,” he said. “So they don’t inject growing embryonic stem cells, but the cells are indeed directly derived from embryonic stem cells, and actually are not completely differentiated, but only part-way (“precursors”).”

“The theory is that once inside the body, the cells will finish specializing to the final cell type, and form an insulative covering over exposed nerves in the spinal cord,” he told LifeNews.com.

Last August, Evan Snyder, a neuroscientist who heads up the stem cell research center at the Burnham Institute for Medical Research in San Diego, warned the research may not be ready for humans.

“There’s a lot of debate among spinal cord researchers that the pre-clinical data itself doesn’t justify the clinical trial,” Snyder, who is working on using neural stem cells himself, says.

Snyder says the mice Geron used to conduct pre-human trial research had more excessive injuries [than] scientists would normally prefer to see prior to trying the procedure on human patients.

He suggests that Geron should have done experiments involving larger animals before seeking FDA permission to use the controversial embryonic stem cells in humans.

Those concerns existed as early as 2005 and may not have been addressed.

Snyder said then that Geron should do more animal testing first to make sure the tests would be on the same injuries humans have.

“I’m not convinced they have done that yet,” Snyder said.

Jerry Silver, a neuroscience professor and stem-cell researcher at Case Western Reserve University in Cleveland, told Knight Ridder back in November 2005 that Geron was moving too fast and needed to do more tests on animals before seeking human patients.

“Frankly, I cannot conceive of a human trial with the use of human embryonic stem cells following immediately from experiments in rodents only,” he said then. “Many treatments that work in rodents to alleviate disease fail miserably in humans.”

Geron came under criticism earlier this year when news surfaced that the application Geron Corporation submitted to the FDA to become the first to engage in human trials of embryonic stem cells was timed with a trigger to make it so it would be considered during the Obama administration. The cloning company worried it would not be approved during the administration of President George W. Bush.

Just days after Obama took office, the FDA suddenly decided to approve Geron’s application for the controversial study.


“There’s stupidity and then there’s just “dumbassedness”. The Obama Administration and FDA okays using embryonic stem cells in humans when every scientist in the field knows they cause tumors and other deadly side effects.” -Boonie



In ALL ARTICLES on November 23, 2009 at 1:05 pm

THIS article is full of so many holes, inconsistencies, half truths, biases and misinformation that it is difficult to even critique it. My comments in blue…

The author  does not make any differentiation between adult/repair stem cells (RSC) and embryonic stem cells (ESC).  Why?  Since he neglected to do this, here are the simple differences between adult/repair stem cells and embryonic stem cells:

RSC = Repair Stem Cells (same as ASC/adult stem cell but a more appropriate name)
•used in bone marrow transplants for 40 years
•can currently treat 100+ diseases
•~zero problems (virtually zero side effects)
•comes from blood, umbilical cords, marrow, fat, nose, breast milk, menstruation, etc etc etc

ESC = embryonic stem cell
•can currently treat zero diseases
•lotsa problems (tumors, rejection, controversy, etc)
•comes from embryos

Now to the article (warning on lies from Australian newspaper)

Warning on cancer risk from stem cell therapy – NICK MILLER, November 23, 2009

EXPERTS fear that a Victorian man with leukaemia may be the first Australian ”infected” with cancer after treatment at a private overseas stem cell therapy centre.

Experts?  Who are the experts? You mention “Stem cell specialists and patient support groups” but you give no credentials.  In fact, the only credentials you list are from the Embryonic stem cell doctor – Dr Kirsten Herbert and as far as I can tell, she did not even comment on this story, although she “plans next month to investigate the case.”  So she hasn’t even investigated the patient’s condition?

Experts don’t “fear”; they assess, research, deduce, investigate and make clinical and scientific observations. They pride themselves on their impartiality and emotionless scientific evaluatory skills.  To say they fear goes agianst the very core of being a scientist.  To say they fear is merely sensationalistic.

Did he go for Leukemia treatment?  Leukemia has been treated with bone marrow transplants utilizing adult/repair stem cells (RSC) for over 40 years without negative side effects. All of a sudden there is a cancer risk? Why?  Did they use embryonic stem cells in a leukemia bone marrow transplant? That would explain it…or did he get leukemia from a stem cell treatment for another disease?  What disease?  There is so little real info here in the opening line it is hard to judge what is really going on.

Stem cell specialists and patient support groups are calling for more public education about the dangers of such services, saying they get hundreds of calls a year from people considering using them – and the numbers are rising.

The companies advertise on the internet and via local information sessions, offering injections of foetal stem cells…

Foetal stem cells are essentially embryonic stem cells.  Embryonic stem cells develop into cysts and tumors.  This procedure has a history of tumors development when used.

…and stem cells extracted from the patient’s spinal cord. They claim to treat conditions such as Alzheimer’s, multiple sclerosis, diabetes, autism and spinal injury.

Private, largely unregulated clinics in Asia and Europe…

Many of them are regulated by oversight groups and standards from 3rd parties.

…charge tens of thousands of dollars plus travel costs.

Please find me one doctor or hospital in the world that pays for your travel costs.

However few have published, clinical proof of their efficacy, relying instead on slick websites and individual testimonies.

Many of them have published studies and trials.  The ONE treatment center this article focuses on does not (is the treatment center ever mentioned or is this just an attempt to paint all of the treatment centers in a bad light because of one?). As for the other qualified and reviewed treatment centers…

Costs for the majority of stem cell treatments range from US$15,000 to $35,000 including hotel but not airfare and food.


• You can get simple intravenous stem cell implants in some countries for as little as US$5000. Even if they are your own stem cells, this means in most instances that the cells are not separated and cultured from their parent tissue or fluid, which costs time and money; so we would not expect the therapy to be as effective for that reason.

You can go to a treatment center that provides inexpensive and lower quality treatments and pay the inexpensive costs…or you can go to a treatment facility that provides the best treatments and pay a higher cost…but you can NOT go to a crappy treatment center and complain about crappy treatments or get the best treatments in the world and complain about appropriate higher costs.

• It also means that the stem cells will not be implanted into a specific area based on the disease; i.e. into the heart for cardiovascular diseases, or into the pancreas for diabetes, or into the spinal canal for neurological diseases such as MS, CP, ALS and Autism.

• Some stem cells cost over US$10,000 to prepare. Some implant procedures cost over US$15,000 to perform. Some clinics include days or even weeks of physical therapy and care, which costs extra.

• In some cases expensive medical devices must be brought in to implant the cells into difficult areas such as the brain or the heart or the lungs, often doubling the cost from the above-mentioned range.

You get what you pay for, the choice is yours!

The stem cell treatments ranged in quality and safety but very few, if any, offered genuine hope, said Dr Kirsten Herbert, a hematologist at the Peter MacCallum Cancer Centre and clinical adviser to the Australian Stem Cell Centre (ASCC).

Australia, like the US, is years behind the rest of the world in regard to Repair Stem Cell treatments.  In fact, up until very recently, the focus in both countries has been entirely on embryonic stem cells.

”One man in Queensland paid $40,000 for a treatment [at a private German clinic] and was told he needed two or three more [visits] for a treatment that I cannot imagine, even with the most blue-sky open mind, could have helped him,” she said.

Which man? What disease, what clinic, what procedure, how many have been treated there for that disease with that procedure?  What are the success rates?  There is no info in here, just the status of her title to carry an empty and unsubstantiated and unreferenced comment. A quick search brought up this info from another article.  I believe this is the article she was quoted out of context from:

“From what Dr Herbert’s read about Mr Tomasiello’s case, she doesn’t understand how the course of treatment prescribed for him will work.  And among other grave concerns she has for his safety, she wants to know if the clinic is using cells that have been cultured using animal products, as that could introduce diseases such as Mad Cow.  The prospect of cells causing cancer also troubles her.  Dr Herbert denies Australia is dragging its feet in stem cell research, saying it is a world leader, and she shrugs off gasps over the use of embryonic stem cells. The creation of embryonic stem cells for scientific use is legal under federal law. All ethical dilemmas ultimately come down to an individual’s personal views, she said. And the testing that we particularly expect to see in stem cells science is what viruses could potentially have infected those cells, so HIV, Hepatitis B, Hepatitis C and some of the other related viruses. And also have those cells been tested for their capacity to form tumours?”

Of course she is worried!  Everything she is concerned about is in regard to embryonic or foetal stem cells.  Repair Stem Cell extraction has about as much negative side-effect potential as giving blood.  She is pro-embryonic stem cell research when so many in the world have abandoned embryonic research has fruitless for developing safe treatments.  She should catch up.  She is also anti-“embryonic caused problems” in the same breath.  What a very awkward position for her.

”But they will take his money and not do anything to look after him when he leaves. If we practised a treatment like that we would be disbarred.”

The top treatment centers do follow ups and make sure the patient’s GP or specialist are contacted and informed.

Dr Herbert plans next month to investigate the case of a Victorian man being treated for leukaemia, which was diagnosed after his recent return from overseas stem cell therapy.

She said it was difficult to prove a link, but there was an international precedent: in February the journal PLoS Medicine reported the case of a teenage Israeli boy who developed brain tumours from experimental stem cell injections at a Russian clinic.

Correct. He was given EMBRYONIC stem cells.  Embryonic stem cells produce tumors because their job is to split and split until they produce a fetus.  You can manipulate them to repair but when they are finished they go back to splitting and often tumors are the result.

The Israeli boy, after he got tumors from embryonic stem cells was then healed with Repair Stem Cells at one of the top treatment centers in the world.  Repair stem cells don’t produce tumors because their job is to repair and fix the tissues and organs of the body.

Dr Herbert said cancer was a rare but possible side-effect of [EMBRYONIC] experimental stem cell therapy.

There has not been a single incident of cancer from adult or repair stem cell treatments…and yet embryonic studies show cyst and tumor growth over and over.  Even the pharmaceutical giant Geron with unlimited resources and finances can’t solve this problem.

”Most stem cells grow in a culture that is exposed to proteins and hormones that encourage growth, and cancer is out-of-control growth, so these [EMBRYONIC stem] cells have a greater potential to cause cancer,” she said.

Amazing how when you drop a word or two, the entire content changes.

Other risks included contamination from animal products used in laboratory processing of the stem cells, which could introduce Creutzfeldt-Jakob disease.

Of the over 2,700 “adult stem cell” clinical trials (1,500+ complete) and 7,540 “adult stem cell” scholarly papers, evidence supports that the risk of RSC treatments are about the same as the risks associated with drawing blood.  (Standard safe practice of lab protocols removes these risks almost entirely.)

Some clinics also instructed patients to go on medication to suppress their immune systems, with potentially dangerous side-effects.

ESC treatments require the use of immunosuppressive drugs (ISD) because ESC are typically allogenic (from outside the patient’s body).  RSC are autologous (from patient’s own body) or from other sources that do NOT require ISD.  ISD are needed to offset the potential of rejection or Graft-versus-host disease (GVHD).  GVHD occurs with ESC.  Standard practice is to HLA type match the donors stem cells to the recipient’s body [“Human leukocyte antigen (HLA) typing is used to match patients and donors for bone marrow or cord blood transplants (also called BMT). HLA are proteins — or markers — found on most cells in your body. Your immune system uses these markers to recognize which cells belong in your body and which do not.”] Unfortunately, even when the ESCs are HLA type matched (both 1+2) you still need ISD because the recipient’s body can still reject the differences in many other aspects of the donated tissue.  RSC DO NOT cause rejection issues or require ISD for GVHD.

”They don’t follow these patients up,” Dr Herbert said. ”They prescribe and wave goodbye without any duty of care.”

The top treatment centers follow up with patients, the sub-standard ones don’t.  Only go to the top treatment centers.  If they do NOT follow up, they will not stay at the top for long.

The financial and emotional risks to patients were just as great, Dr Herbert said. ”Most likely, the treatment you are going to receive is not going to work.” It was important not to demonise people who sought these cures, but instead to help them find the right advice.

RSC are treating about 80% of diseases successfully and more people are discovering their benefits every day.  RSC give significant improvements to about 2/3 of the patients who are treated.

Patient advocacy groups are meeting stem cell experts in Canberra today to discuss a co-ordinated approach to public education on overseas experimental treatments.

You said this almost identical sentence above:

Advocacy groups for people targeted as possible clients will meet in Canberra today to discuss how to protect people from being emotionally and financially exploited.”

The ASCC is about to release a patient handbook to help people critically analyse stem cell treatments. It has a list of questions to ask before signing up.



In BEST OF THE BEST on November 23, 2009 at 2:51 am

THis article has been revised. Please go here: https://repairstemcell.wordpress.com/2009/11/23/australian-swiss-cheese-leaves-bad-taste/

Neighborly Care Keeps Stem Cells Young

In SCIENCE & STEM CELLS on October 8, 2009 at 5:25 pm

An immunofluorescence image of the tip of the Drosophila testis, showing male germline stem cells and their daughters (green) responding to self renewal signals from the stem cell niche. Somatic stem cells, known as cyst progenitor cells, and differentiating cyst cells are labeled in red. (Credit: Dr. Monica Boyle)

via Neighborly Care Keeps Stem Cells Young.


In STEM CELLS IN THE NEWS on August 27, 2009 at 8:15 am
Geron Comments on FDA Hold on Spinal Cord Injury Trial

MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq:GERN) today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

As biologic therapeutics advance in clinical trials, it is common practice to optimize product characteristics, improve manufacturing efficiency and scale, and to test the product in multiple disease models. As part of these ongoing efforts at Geron with respect to GRNOPC1, various animal studies were, and continue to be, performed to characterize the product’s effects in vivo. In previous animal studies of GRNOPC1 using materials that passed release specifications, a very low frequency of injected animals developed microscopic cysts in the regenerating injury site. These cysts were non-proliferative, confined to the injury site, and had no adverse effects on the animals. No animals developed teratomas or any other ectopic structure. Cysts of much larger size appear in the spinal cord scar tissue of up to 50% of patients with spinal cord injury.

A just completed animal study showed a higher frequency of cysts, although their characteristics were similar to the cysts seen in previous studies: non-proliferative, confined to the injury site, smaller than the injury cavity and not associated with adverse clinical outcomes.

As part of our ongoing product improvement efforts, new candidate markers and assays for product release have been identified that are linked with cyst formation across all animal studies in which cysts were found. Importantly, a manufactured lot of GRNOPC1 that was assessed using these markers and assays showed no cysts in another recently concluded animal study in spinal cord injured rats.

We have submitted these data to the FDA and are in discussions with the agency to answer its questions and proceed with the clinical trial. We are committed to the optimization of all our hESC-based products as we improve the manufacturing process and identify improved product release criteria.

%d bloggers like this: